Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with decompensated cirrhosis: Table 12
  • There are now several regimens with DAAs that are recommended
    • Choice of regimen depends on genotype, treatment experience, and ribavirin eligibility

Action required

Keywords: Hepatitis C, Hepatitis C-Posttransplant Management, Hepatitis C-Special Populations, Hepatitis C-Sustained Virologic Response, Hepatitis C-Treatment

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.